Lexicon Pharmaceuticals (LXRX) News Today

HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Lexicon Pharmaceuticals in a report on Wednesday.

Hennion & Walsh Asset Management Inc. bought a new position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 542,899 shares of the biopharmaceutical company's s

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Stock analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for Lexicon Pharmaceuticals in a research note issued on Tuesday, August 13th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceu

HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Lexicon Pharmaceuticals in a research note on Tuesday.

Vanguard Group Inc. raised its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 7.0% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 6,401,225 shares of the biopharmaceutical company's stock after purchasing an additional 420,854 shares

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.01. Lexicon Pharmaceuticals had a negative net margin of 8,311.12% and a negative return on equity of 108.54%. The firm had revenue of $1.65 million for the quarter, compared to analyst estimates of $2.74 million. During the same quarter in the prior year, the business posted ($0.22) EPS.

HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Friday.

Lexicon Pharmaceuticals (NASDAQ:LXRX) will be releasing earnings after the market closes on Thursday, August 1, Zacks reports.

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Up 4.1%

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 7.1%

HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Lexicon Pharmaceuticals in a report on Tuesday.

GSA Capital Partners LLP lowered its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 62.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 293,333 shares of the biopharmaceutical company's s

StockNews.com raised shares of Lexicon Pharmaceuticals to a "sell" rating in a research note on Tuesday.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totalling 21,570,000 shares, a decline of 14.2% from the May 31st total of 25,140,000 shares. Based on an average trading volume of 2,810,000 shares, the short-interest ratio is currently 7.7 days.

HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Stock analysts at HC Wainwright issued their Q2 2024 earnings per share estimates for shares of Lexicon Pharmaceuticals in a research note issued to investors on Monday, June 17th. HC Wainwright analyst J. Pantginis forecasts that the bi

BVF Inc. IL boosted its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 22.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,435,632 shares of the biopharmaceutica

Lexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Crosses Above 200 Day Moving Average of $1.84

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) was the recipient of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 23,440,000 shares, an increase of 16.5% from the April 15th total of 20,120,000 shares. Based on an average trading volume of 4,450,000 shares, the short-interest ratio is currently 5.3 days.